Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24440968 | 0.76 | CNR2 (0.58) | LMNACNR2RAB9ACNR1SMN1; SMN2 | |
| SCHEMBL6566922 | 0.74 | SMN1; SMN2 (0.69) | LMNAALDH1A1GAACNR1SMN1; SMN2 | |
| SCHEMBL6071297 | 0.74 | CNR2 (0.48) | LMNACYP2C19ALDH1A1CNR2RAB9A | |
| SCHEMBL30302003 | 0.74 | ALDH1A1 (0.51) | LMNACYP2C19ALDH1A1CNR2RAB9A | |
| SCHEMBL1942780 | 0.65 | MEN1 (0.63) | LMNAALDH1A1GAARAB9A | |
| SCHEMBL3885073 | 0.64 | RAB9A (0.76) | LMNACYP2C19RAB9AATMTSHR | |
| SCHEMBL9764606 | 0.64 | HIF1A (0.64) | LMNACYP2C19ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL15437067 | 0.63 | ATM (0.75) | LMNACYP2C19ALDH1A1GAARAB9A | |
| Hydrochloric Acid SCHEMBL3889023 | 0.63 | RAB9A (0.74) | LMNACYP2C19RAB9AATMTSHR | |
| SCHEMBL13118343 | 0.62 | LMNA (1.00) | LMNACYP2C19ALDH1A1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827619-B2 | Dichlorophenol HSD17B13 inhibitors and uses thereof | INIPHARM, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230278981-A1 | DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2022103960-A1 | DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278981-A1 | DICHLOROPHENOL HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | LMNA 2067/4885CYP2C19 61/4885KDR 3978/4885 |
| US-11827619-B2 | Dichlorophenol HSD17B13 inhibitors and uses thereof | HSD17B1, HSD17B3, HSD17B13 | LMNA 2067/4885CYP2C19 61/4885KDR 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.